Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PDXK | O00764 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549300 | 0.83 | ALDH1A1 (0.36) | RECQLPDXKALDH1A1NPSR1TDP1 | |
| SCHEMBL20876899 | 0.80 | PDXK (0.42) | RECQLPDXKALDH1A1NPC1RAB9A | |
| SCHEMBL30513481 | 0.80 | PDXK (0.42) | RECQLPDXKALDH1A1NPC1RAB9A | |
| SCHEMBL1141323 | 0.79 | ALDH1A1 (0.42) | ALDH1A1NPSR1TDP1 | |
| SCHEMBL30833526 | 0.79 | ALDH1A1 (0.42) | ALDH1A1NPSR1TDP1 | |
| SCHEMBL335739 | 0.78 | RECQL (0.39) | RECQLPDXKNPC1RAB9APOLB | |
| SCHEMBL22990491 | 0.78 | RECQL (0.39) | RECQLPDXKNPC1RAB9APOLB | |
| SCHEMBL9649790 | 0.78 | CPB2 (0.50) | RECQLNPC1RAB9APOLB | |
| SCHEMBL335231 | 0.78 | RECQL (0.39) | RECQLPDXKNPC1RAB9APOLB | |
| SCHEMBL487778 | 0.78 | CYP11B1 (0.50) | RECQLPDXKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105884679-A | Method for preparing 5, 6-dichloro-3-hydroxymethylpyridine-2-phenol from DCTF rectification and short-steaming residues | 江苏天宇检测技术有限公司 | 2016-08-24 | — | — | CN | claimed |
| US-11912695-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912695-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-111148735-B | Nitrogen-containing heteroaryl compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2023-08-08 | — | — | CN | disclosed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| EP-4172156-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | Philip Morris Products S.A. (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-3693358-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-02-22 | — | — | EP | disclosed |
| CN-115698002-A | Compositions and methods for parasite control | 菲利普莫里斯生产公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114591226-A | Preparation method of nicotinaldehyde derivative | 南京益恩生物科技有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-6169183-B1 | REACTING 2,3-DIHALOPYRIDINE WITH CARBON MONOXIDE AND ALKANOL IN PRESENCE OF WEAK BASE AND COMPLEX OF PALLADIUM WITH SPECIFIED BIS(DIPHENYLPHOSPHINE), WHEREIN REACTION IS STOPPED AS SOON AS MAXIMUM CONCENTRATION OF ESTER IS ACHIEVED | LONZA, LTD. (CH) | 2001-01-02 | — | — | US | disclosed |
| US-6162921-A | Process for preparing pyridinecarboxylic esters | LONZA, LTD (CH) | 2000-12-19 | — | — | US | disclosed |
| WO-2000046196-A1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |
| US-6022973-A | Process for preparing pyridinecarboxylic esters | LONZA LTD. (CH) | 2000-02-08 | — | — | US | disclosed |
| US-5925765-A | Process for preparing pyridinecarboxylic esters | LONZA AG (CH) | 1999-07-20 | — | — | US | disclosed |
| EP-0820987-A1 | Process for the preparation of pyridine-2,3-dicarboxylic acid esters | LONZA AG (CH) | 1998-01-28 | — | — | EP | disclosed |
| EP-0820986-A1 | Process for the preparation of pyridine carboxylic acid esters | LONZA AG (CH) | 1998-01-28 | — | — | EP | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | TRHDE, CUTA, PIGS | RECQL 3071/4885PDXK 4354/4885ALDH1A1 2870/4885 |
| US-11912695-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | RECQL 3447/4885PDXK 2726/4885ALDH1A1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.